MedKoo Cat#: 529102 | Name: AT-9283 HCl
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

AT-9283 is a small-molecule multi-targeted kinase inhibitor with potent bioactivity against Aurora A and B kinases, JAK2, JAK3, and Abl kinases. It exhibits IC₅₀ values of 3 nM for Aurora B, 21 nM for Aurora A, 1.2 nM for JAK2, 1.1 nM for JAK3, and approximately 3 nM for Abl (including the T315I mutant). In preclinical cancer models, AT-9283 induces polyploidy and apoptosis in tumor cells due to mitotic disruption from Aurora inhibition, and demonstrates antiproliferative effects across a range of hematologic malignancies and solid tumors. It has shown in vivo efficacy in xenograft models and entered early-phase clinical trials, though dose-limiting toxicities such as neutropenia were observed.

Chemical Structure

AT-9283 HCl
AT-9283 HCl
CAS#896466-61-8 (HCl)

Theoretical Analysis

MedKoo Cat#: 529102

Name: AT-9283 HCl

CAS#: 896466-61-8 (HCl)

Chemical Formula: C19H24ClN7O2

Exact Mass: 0.0000

Molecular Weight: 417.89

Elemental Analysis: Chemical Formula: C19H24ClN7O2 Exact Mass: 417.1680 Molecular Weight: 417.8980 Elemental Analysis: C, 54.61; H, 5.79; Cl, 8.48; N, 23.46; O, 7.66

Price and Availability

Size Price Availability Quantity
500mg USD 2,450.00 4 Weeks
1g USD 3,250.00 4 Weeks
2g USD 5,650.00 4 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Synonym
AT-9283; AT9283; AT 9283; AT-9283 HCl; AT-9283 hydrochloride
IUPAC/Chemical Name
1-cyclopropyl-3-(3-(6-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazol-4-yl)urea hydrochloride
InChi Key
NHFNYIVVGIXBPD-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H23N7O2.ClH/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26;/h1,4,9-10,13H,2-3,5-8,11H2,(H,20,25)(H,22,23)(H2,21,24,27);1H
SMILES Code
O=C(NC1=CNN=C1C2=NC3=CC=C(CN4CCOCC4)C=C3N2)NC5CC5.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 417.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Matsueda S, Gao H, Efferson CL, Tsuda N, Ishiyama S, Li Y, Ioannides MG, Fisk B, Peoples GE, Ioannides CG. N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells. Anticancer Res. 2009 Jul;29(7):2427-35. PubMed PMID: 19596910. 2: Li Y, Matsueda S, Efferson CL, Tsuda N, Kawano K, Gao H, Peoples GE, Ioannides CG. Distinct patient responses to activation of T-cells by free HER-2, G89 (777-789) and protected LRMK-linked HER-2, {AE-39 [p776 (Ava-774-788)], AE-47 [(Ava-776-788)] and AE-37[p776 (774-788)]} peptides could lead to development of personalized cancer vaccines. Anticancer Res. 2009 Jan;29(1):41-58. PubMed PMID: 19331132. 3: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Sep;32(7):517-48. doi: 10.1358/mf.2010.32.7.1549223. PubMed PMID: 21069103. 4: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Jan-Feb;32(1):47-86. PubMed PMID: 20383346. 5: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Oct;30(8):643-72. PubMed PMID: 19088949. 6: Díaz-Ortega JL, Bennett JV, Castañeda-Desales D, Quintanilla DM, Martínez D, de Castro JF. Booster immune response in children 6-7 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection. Vaccine. 2014 Jun 17;32(29):3680-6. doi: 10.1016/j.vaccine.2014.04.031. PubMed PMID: 24837512. 7: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Dec;28(10):719-40. PubMed PMID: 17235418. 8: Xu J, You C, Zhang S, Huang S, Cai B, Wu Z, Li H. Angiogenesis and cell proliferation in human craniopharyngioma xenografts in nude mice. J Neurosurg. 2006 Oct;105(4 Suppl):306-10. PubMed PMID: 17328281. 9: Papacchini F, Goracci C, Sadek FT, Monticelli F, Garcia-Godoy F, Ferrari M. Microtensile bond strength to ground enamel by glass-ionomers, resin-modified glass-ionomers, and resin composites used as pit and fissure sealants. J Dent. 2005 Jul;33(6):459-67. PubMed PMID: 15935265. 10: Vamvakidès A. [Anticonvulsant and forced swim anti-immobility effects of tetrahydro-N, N-dimethyl-2,2-diphenyl-3-furanemethanamine (AE37): common action mechanism?]. Ann Pharm Fr. 2002 Mar;60(2):88-92. Review. French. PubMed PMID: 11976553. 11: Gündoğdu C, Arslan R, Arslan MO, Gicik Y. [Evaluation of cystic and alveolar echinococcosis cases in people in Erzurum and surrounding cities.]. Turkiye Parazitol Derg. 2005;29(3):163-6. Turkish. PubMed PMID: 17160814. 12: Shinagawa K, Tachihara R, Matsusaka N, Sugii S. Immunological cross-reactivity of the fragments of staphylococcal enterotoxins A and E generated by digestion of proteolytic enzymes. J Vet Med Sci. 1991 Apr;53(2):223-7. PubMed PMID: 1713793.